Literature DB >> 17998146

Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection.

Klaus Juergen Schmitz1, Jeremias Wohlschlaeger, Hauke Lang, Georgios Charalambos Sotiropoulos, Massimo Malago, Karen Steveling, Henning Reis, Vito Rosario Cicinnati, Kurt Werner Schmid, Hideo Andreas Baba.   

Abstract

BACKGROUND/AIMS: The aim of the study was to determine the prognostic relevance of AKT and extracellular regulated kinases (ERK1/2), which are implied in the regulation of cell proliferation and apoptosis, in hepatocellular carcinoma (HCC).
METHODS: This study comprised a series of 208 patients incorporating HCCs treated either by surgical resection (n = 109) or liver transplantation (n = 99). Immunohistochemically demonstrated phospho-ERK1/2 (pERK1/2) and phospho-AKT (pAKT) was correlated with a series of clinico-pathologically relevant parameters (EGFR, Cyclin-D1, HCV/HBV infection, liver cirrhosis, chronic alcohol abuse), proliferative activity, and apoptosis.
RESULTS: Activation of ERK1/2 correlated statistically with the presence of HCV infection. pERK1/2 (P < 0.001) and pAKT (P = 0.052) expression showed a significant correlation with a decreased overall survival (OS). In multivariate Cox regression analysis pERK1/2 was identified as an independent prognostic parameter in HCC (P = 0.026).
CONCLUSIONS: Activation of ERK1/2 in HCC cancer indicates aggressive tumour behaviour and constitutes an independent prognostic factor. Furthermore our data confirm that HCV infection activates the ERK pathway and thereby might contribute to HCC carcinogenesis. Immunohistochemical determination of pERK1/2 status can thus be proposed as a promising candidate for the identification of high risk patients who may benefit from new anticancer drugs targeting the ERK-pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17998146     DOI: 10.1016/j.jhep.2007.08.018

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  115 in total

1.  Extracellular signal-regulated kinase (ERK) expression and activation in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.

Authors:  Stamatios Theocharis; Ioly Kotta-Loizou; Jerzy Klijanienko; Constantinos Giaginis; Paraskevi Alexandrou; Eougken Dana; Jose Rodriguez; Efstratios Patsouris; Xavier Sastre-Garau
Journal:  Tumour Biol       Date:  2014-03-30

2.  Liver-specific knockout of GRP94 in mice disrupts cell adhesion, activates liver progenitor cells, and accelerates liver tumorigenesis.

Authors:  Wan-Ting Chen; Chun-Chih Tseng; Kyle Pfaffenbach; Gary Kanel; Biquan Luo; Bangyan L Stiles; Amy S Lee
Journal:  Hepatology       Date:  2014-01-27       Impact factor: 17.425

3.  Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.

Authors:  Roberta Schmieder; Florian Puehler; Roland Neuhaus; Maria Kissel; Alex A Adjei; Jeffrey N Miner; Dominik Mumberg; Karl Ziegelbauer; Arne Scholz
Journal:  Neoplasia       Date:  2013-10       Impact factor: 5.715

4.  Markers of Hippo-Pathway Activity in Tumor Forming Liver Lesions.

Authors:  Henning Reis; Stefanie Bertram; Leona Pott; Ali Canbay; Anja Gallinat; Hideo Andreas Baba
Journal:  Pathol Oncol Res       Date:  2016-06-08       Impact factor: 3.201

Review 5.  Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells.

Authors:  Katrin Eurich; Mayuko Segawa; Satoko Toei-Shimizu; Emiko Mizoguchi
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

6.  AKT and PTEN expression in human gastrointestinal carcinoid tumors.

Authors:  Susan C Pitt; Ruth Davis; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Am J Transl Res       Date:  2009-02-28       Impact factor: 4.060

7.  The expression of chitinase 3-like 1: a novel prognostic predictor for hepatocellular carcinoma.

Authors:  Jing-Jing Pan; Yong-Sheng Ge; Ge-Liang Xu; Wei-Dong Jia; Wei-Feng Liu; Jian-Sheng Li; Wen-Bin Liu
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-23       Impact factor: 4.553

Review 8.  Molecular targeted therapies in hepatocellular carcinoma.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

9.  Estrogen receptor-dependent genomic expression profiles in breast cancer cells in response to fatty acids.

Authors:  Faizeh Alquobaili; Stacy-Ann Miller; Seid Muhie; Agnes Day; Marti Jett; Rasha Hammamieh
Journal:  J Carcinog       Date:  2010-02-04

10.  Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations.

Authors:  Qinglong Li; Zhulin Yang
Journal:  J Exp Clin Cancer Res       Date:  2009-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.